2.1. Study Participants
MALIGNANCIES, GASTRIC CANCER
This study is a single-center, prospective, randomized investigation aimed at assessing the efficacy of perioperative immunonutrition in patients undergoing radical gastrectomy for gastric cancer. The cohort encompassed patients who underwent radical gastrectomy from June 2022 to June 2023 at the Peking Union Medical College Hospital.Inclusion Criteria: 1. Pathologically confirmed diagnosis of gastric cancer; 2. Complete clinical data; 3. Aged 18–80 years; 4. Absence of radiotherapy or chemotherapy interventions within the four weeks before surgery; 5. Patient’s informed consent and signature on the consent form.Exclusion Criteria: 1. Manifestation of severe clinical symptoms or comorbidities; 2. Diagnoses of other concurrent malignancies; 3. Patients who are pregnant or lactating; 4. Inability to take oral or enteral nutrition during the perioperative period; 5. Perioperative administration of fat emulsions enriched in Based on the chosen perioperative nutritional support, patients were randomized into either the study group (benefiting from enteral nutrition supplemented with immunonutrients) or the control group. This study strictly adhered to the ethical principles of medical research involving patients, as laid out in the Declaration of Helsinki. Ethical clearance for the study was approved by the ethics committee of the Peking Union Medical College Hospital, documented under the code KS2022530 and dated 9 February 2022. All enrolled participants were included in the research after a detailed explanation of the study protocol and their written informed consent, or that of their family members was procured. The flowchart of our study is shown in 